Have a personal or library account? Click to login

Molecular and Immunohistochemical Biomarkers in Colorectal Carcinoma - A Single Center Study

Balkan Journal of Medical Genetics
Volume 28 (2025): Issue 1 (June 2025)
By:
Open Access
|Oct 2025

References

  1. Seufferlein, Thomas, Carolina Simões, Fernando Kude, and Thomas J. Ettrich. “Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?” Visceral Medicine 35, no. 4 (August 2019): 259–64. https://doi.org/10.1159/000500617.
    Search in Google ScholarBack to article
  2. Li, Jiexi, Xingdi Ma, Deepavali Chakravarti, Shabnam Shalapour, and Ronald A. DePinho. “Genetic and Biological Hallmarks of Colorectal Cancer.” Genes & Development 35, no. 11–12 (June 2021): 787–820. https://doi.org/10.1101/gad.348226.120.
    Search in Google ScholarBack to article
  3. Min L, Chen J, Yu M, Liu D. Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis. J Clin Med. 2023 Jan 4;12(2):408. doi: 10.3390/jcm12020408.
    Open DOISearch in Google ScholarBack to article
  4. Effendi-Ys, Rustam. “Colonoscopy, Biomarkers, and Targeted Therapy in Colorectal Cancer.” Acta Medica Indonesiana 54, no. 3 (July 2022): 476–86.
    Search in Google ScholarBack to article
  5. Crutcher, Madison, and Scott Waldman. “Biomarkers in the Development of Individualized Treatment Regimens for Colorectal Cancer.” Frontiers in Medicine 9 (2022): 1062423. https://doi.org/10.3389/fmed.2022.1062423.
    Search in Google ScholarBack to article
  6. Martini, Giulia, Rodrigo Dienstmann, Javier Ros, Iosune Baraibar, Jose Luis Cuadra-Urteaga, Francesc Salva, Davide Ciardiello, et al. “Molecular Subtypes and the Evolution of Treatment Management in Metastatic Colorectal Cancer.” Therapeutic Advances in Medical Oncology 12 (2020): 1758835920936089. https://doi.org/10.1177/1758835920936089.
    Search in Google ScholarBack to article
  7. Rawla, Prashanth, Adam Barsouk, Andreas V. Hadjinicolaou, and Alexander Barsouk. “Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer.” Medical Sciences (Basel, Switzerland) 7, no. 8 (July 30, 2019): 83. https://doi.org/10.3390/medsci7080083.
    Search in Google ScholarBack to article
  8. Shek, Dmitrii, Liia Akhuba, Matteo S. Carlino, Adnan Nagrial, Tania Moujaber, Scott A. Read, Bo Gao, and Golo Ahlenstiel. “Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes.” Cancers 13, no. 17 (August 27, 2021): 4345. https://doi.org/10.3390/cancers13174345.
    Search in Google ScholarBack to article
  9. Doleschal, Bernhard, Andreas Petzer, and Holger Rumpold. “Current Concepts of Anti-EGFR Targeting in Metastatic Colorectal Cancer.” Frontiers in Oncology 12 (2022): 1048166. https://doi.org/10.3389/fonc.2022.1048166.
    Search in Google ScholarBack to article
  10. Zhang, Xuan, Tao Wu, Xinyi Cai, Jianhua Dong, Cuifeng Xia, Yongchun Zhou, Rong Ding, et al. “Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.” Frontiers in Immunology 13 (2022): 795972. https://doi.org/10.3389/fimmu.2022.795972.
    Search in Google ScholarBack to article
  11. Guarini, Chiara, Teresa Grassi, Gaetano Pezzicoli, and Camillo Porta. “Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.” International Journal of Molecular Sciences 22, no. 13 (June 24, 2021): 6813. https://doi.org/10.3390/ijms22136813.
    Search in Google ScholarBack to article
  12. Gutierrez, Martin E., Kristin S. Price, Richard B. Lanman, Rebecca J. Nagy, Irfan Shah, Shivam Mathura, Michael Mulcahy, Andrew D. Norden, and Stuart L. Goldberg. “Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer.” JCO Precision Oncology, no. 3 (December 2019): 1–9. https://doi.org/10.1200/PO.19.00274.
    Search in Google ScholarBack to article
  13. Janani, Balakarthikeyan, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi, et al. “EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges.” Vaccines 10, no. 4 (March 24, 2022): 499. https://doi.org/10.3390/vaccines10040499.
    Search in Google ScholarBack to article
  14. Mármol, Inés, Cristina Sánchez-de-Diego, Alberto Pradilla Dieste, Elena Cerrada, and María Jesús Rodriguez Yoldi. “Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.” International Journal of Molecular Sciences 18, no. 1 (January 19, 2017): 197. https://doi.org/10.3390/ijms18010197.
    Search in Google ScholarBack to article
  15. Zhu, Gongmin, Lijiao Pei, Hongwei Xia, Qiulin Tang, and Feng Bi. “Role of Oncogenic KRAS in the Prognosis, Diagnosis and Treatment of Colorectal Cancer.” Molecular Cancer 20, no. 1 (November 6, 2021): 143. https://doi.org/10.1186/s12943-021-01441-4.
    Search in Google ScholarBack to article
  16. László, Loretta, Anita Kurilla, Tamás Takács, Gyöngyi Kudlik, Kitti Koprivanacz, László Buday, and Virag Vas. “Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology.” Cells 10, no. 3 (March 17, 2021): 667. https://doi.org/10.3390/cells10030667.
    Search in Google ScholarBack to article
  17. Li, Yang, Jun Xiao, Tiancheng Zhang, Yanying Zheng, and Hailin Jin. “Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia.” Frontiers in Oncology 12 (2022). https://www.frontiersin.org/articles/10.3389/fonc.2022.897548.
    Search in Google ScholarBack to article
  18. Afrăsânie, Vlad-Adrian, Mihai Vasile Marinca, Teodora Alexa-Stratulat, Bogdan Gafton, Marius Păduraru, Anca Maria Adavidoaiei, Lucian Miron, and Cristina Rusu. “KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer - Practical Implications for the Clinician.” Radiology and Oncology 53, no. 3 (September 24, 2019): 265–74. https://doi.org/10.2478/raon-2019-0033.
    Search in Google ScholarBack to article
  19. Ciombor, Kristen K., John H. Strickler, Tanios S. Bekaii-Saab, and Rona Yaeger. “BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 40, no. 24 (August 20, 2022): 2706–15. https://doi.org/10.1200/JCO.21.02541.
    Search in Google ScholarBack to article
  20. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. J Clin Oncol. 2019 Jun 10;37(17):1460–1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.
    Open DOISearch in Google ScholarBack to article
  21. Lote, Hazel, Naureen Starling, Rille Pihlak, and Marco Gerlinger. “Advances in Immunotherapy for MMR Proficient Colorectal Cancer.” Cancer Treatment Reviews 111 (December 1, 2022). https://doi.org/10.1016/j.ctrv.2022.102480.
    Search in Google ScholarBack to article
  22. De’ Angelis, Gian Luigi, Lorena Bottarelli, Cinzia Azzoni, Nicola De’ Angelis, Gioacchino Leandro, Francesco Di Mario, Federica Gaiani, and Francesca Negri. “Microsatellite Instability in Colorectal Cancer.” Acta Bio-Medica: Atenei Parmensis 89, no. 9-S (December 17, 2018): 97–101. https://doi.org/10.23750/abm.v89i9-S.7960.
    Search in Google ScholarBack to article
  23. Cohen, Romain, Benoît Rousseau, Joana Vidal, Raphaël Colle, Luis A. Diaz, and Thierry André. “Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.” Targeted Oncology 15, no. 1 (February 2020): 11–24. https://doi.org/10.1007/s11523-019-00690-0
    Search in Google ScholarBack to article
  24. Cohen, Romain, Thomas Pudlarz, Jean-François Delattre, Raphaël Colle, and Thierry André. “Molecular Targets for the Treatment of Metastatic Colorectal Cancer.” Cancers 12, no. 9 (August 20, 2020): 2350. https://doi.org/10.3390/cancers12092350.
    Search in Google ScholarBack to article
  25. Martianov, Aleksandr S., Natalia V. Mitiushkina, Anastasia N. Ershova, Darya E. Martynenko, Mikhail G. Bubnov, Priscilla Amankwah, Grigory A. Yanus, et al. “KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.” International Journal of Molecular Sciences 24, no. 5 (January 2023): 4868. https://doi.org/10.3390/ijms24054868.
    Search in Google ScholarBack to article
  26. Battaglin, Francesca, Madiha Naseem, Heinz-Josef Lenz, and Mohamed E. Salem. “Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives.” Clinical Advances in Hematology & Oncology: H&O 16, no. 11 (November 2018): 735–45.
    Search in Google ScholarBack to article
  27. Cheng, Xiaoqing. “A Comprehensive Review of HER2 in Cancer Biology and Therapeutics.” Genes 15, no. 7 (July 2024): 903. https://doi.org/10.3390/genes15070903.
    Search in Google ScholarBack to article
  28. Achalla, Lakshmi Sai Vijay, Raju K Shinde, Sangita Jogdand, and Sahitya Vodithala. “Review of the Role of HER2/Neu in Colorectal Carcinomas.” Cureus 14, no. 5 (May 27, 2022): e25409. https://doi.org/10.7759/cureus.25409.
    Search in Google ScholarBack to article
  29. Mohamed, Ali Abdulnabi, David K. Lau, and Ian Chau. “HER2 Targeted Therapy in Colorectal Cancer: New Horizons.” Cancer Treatment Reviews 105 (April 1, 2022). https://doi.org/10.1016/j.ctrv.2022.102363.
    Search in Google ScholarBack to article
  30. Ahcene Djaballah, Selma, Francesca Daniel, Anna Milani, Gianmarco Ricagno, and Sara Lonardi. “HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.” American Society of Clinical Oncology Educational Book, no. 42 (July 1, 2022): 219–32. https://doi.org/10.1200/EDBK_351354.
    Search in Google ScholarBack to article
  31. Siena, S., A. Sartore-Bianchi, S. Marsoni, H. I. Hurwitz, S. J. McCall, F. Penault-Llorca, S. Srock, A. Bardelli, and L. Trusolino. “Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) Oncogene in Colorectal Cancer.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 29, no. 5 (May 1, 2018): 1108–19. https://doi.org/10.1093/annonc/mdy100.
    Search in Google ScholarBack to article
  32. Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F, Ardizzoni A, Amatu A, Bencardino K, Valtorta E, Grassi E, Torri V, Bonoldi E, Sapino A, Vanzulli A, Regge D, Cappello G, Bardelli A, Trusolino L, Marsoni S, Siena S. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020 Sep;5(5):e000911. doi: 10.1136/esmoopen-2020-000911.
    Open DOISearch in Google ScholarBack to article
  33. Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024 Jan 20;42(3):258–265. doi: 10.1200/JCO.22.02636. Epub 2023 Oct 4.
    Open DOISearch in Google ScholarBack to article
  34. Chen, Xiang, Ling-Juan Chen, Xiao-Fei Peng, Ling Deng, Yan Wang, Jiu-Jiang Li, Dong-Li Guo, and Xiao-Hua Niu. “Anti-PD-1/PD-L1 Therapy for Colorectal Cancer: Clinical Implications and Future Considerations.” Translational Oncology 40 (December 1, 2023): 101851. https://doi.org/10.1016/j.tranon.2023.101851.
    Search in Google ScholarBack to article
  35. Noh, Byeong-Joo, Jae Young Kwak, and Dae-Woon Eom. “Immune Classification for the Pd-L1 Expression and Tumour-Infiltrating Lymphocytes in Colorectal Adenocarcinoma.” BMC Cancer 20, no. 1 (January 28, 2020): 58. https://doi.org/10.1186/s12885-020-6553-9.
    Search in Google ScholarBack to article
  36. Oliveira, André F., Luís Bretes, and Irene Furtado. “Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer.” Frontiers in Oncology 9 (2019): 396. https://doi.org/10.3389/fonc.2019.00396.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/bjmg-2025-0008 | Journal eISSN: 2199-5761
Journal RSS Feed
Language: English
Published on: Oct 8, 2025
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
colorectal carcinoma,
biomarkers,
KRAS,
BRAF,
HER2,
PDL-1
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2025 B Krsteska, V Filipovski, K Kubelka-Sabit, Dz Jasar, N Velickova, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 28 (2025): Issue 1 (June 2025)Next article